Investigating immune profiles in inflammatory muscle diseases
Official title: Immunophenotypes in the Idiopathic Inflammatory Myopathies
Funded at Vanderbilt University Medical Center · NIH-10877796 · Data updated 2026-11-12
This study is looking at how the immune system affects muscle inflammation in people with idiopathic inflammatory myopathies (IIM) to find new ways to help improve treatment and care for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | July 26, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $163,836 |
| NIH project number | 5K08AR080808-03 |
| Project ID | NIH-10877796 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic inflammatory myopathies.
✕Less likely to help
Patients with other types of muscle diseases or those without a diagnosis of inflammatory myopathy may not benefit from this research.
What this research studies
This research focuses on understanding the immune system's role in idiopathic inflammatory myopathies (IIM), a group of diseases that cause muscle inflammation. The project aims to identify specific immune signatures and transcriptional changes associated with these conditions by analyzing patient samples. By correlating these immune features with clinical outcomes, the research seeks to uncover potential new therapeutic targets and improve patient care. Patients with IIM may have their disease progression better understood through this innovative approach.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment options for patients with inflammatory myopathies.
How similar studies have gone: Other research has shown promise in using immune profiling to understand autoimmune diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Wilfong, Erin M — Vanderbilt University Medical Center
- Study coordinator: Wilfong, Erin M
Related research
Other NIH-funded projects on the same topics.
-
Immunophenotypes in inflammatory myopathies and linked lung disease
A physician-scientist at Vanderbilt is pursuing how immune cells and gene activity differ in Idiopathic Inflammatory Myopathies to find clues for better treatments.
-
Understanding Immune Differences in Muscle Inflammation
This project aims to understand the unique immune system features in people with idiopathic inflammatory myopathies to find better ways to help them.
-
Exploring how specific genetic elements contribute to autoimmune muscle diseases.
This study is looking at how certain genetic elements might cause muscle inflammation in people with autoimmune diseases that affect their muscles, and it hopes to find new ways to treat these conditions more effectively and with fewer side effects.
-
How high-density lipoprotein function is affected in patients with inflammatory muscle diseases
This study is looking at how a type of good cholesterol called HDL, which usually helps keep your blood vessels healthy, doesn't work properly in people with idiopathic inflammatory myopathies (IIM), and it aims to find out why this happens and how it might lead to heart problems, so we can discover new ways to help.
-
MTS109 treatment for refractory autoimmune diseases
This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.
-
AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis
This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.